KANAMYCIN Drug Patent Profile

Which patents cover Kanamycin, and when can generic versions of Kanamycin launch?

Kanamycin is a drug marketed by Hikma, Abraxis Pharm, Fresenius Kabi Usa, Intl Medication, Loch, Pharmafair, Solopak, Warner Chilcott, and Watson Labs. and is included in thirteen NDAs.

The generic ingredient in KANAMYCIN is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.

Summary for KANAMYCIN

US Patents:	0
Applicants:	9
NDAs:	13
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	13
Patent Applications:	2,932
DailyMed Link:	KANAMYCIN at DailyMed

Recent Clinical Trials for KANAMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
McMaster University	N/A
Centre for the AIDS Programme of Research in South Africa	Phase 4
Rede TB	Phase 3

See all KANAMYCIN clinical trials

US Patents and Regulatory Information for KANAMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	KANAMYCIN	kanamycin sulfate	INJECTABLE;INJECTION	062324-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Solopak	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	062605-003	Feb 26, 1986		DISCN	No	No
Fresenius Kabi Usa	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	065111-002	Dec 17, 2002		DISCN	No	No

Market Dynamics and Financial Trajectory for Kanamycin

Last updated: February 14, 2026

Overview

Kanamycin is an aminoglycoside antibiotic used primarily for treating severe bacterial infections, especially multi-drug resistant tuberculosis (MDR-TB). It has been available since the 1950s and is mainly administered via injectable formulation. Despite its long-standing presence, the market for kanamycin faces shifts driven by evolving resistance patterns, regulatory changes, and advances in alternative therapies.

Market Size and Growth

• The global aminoglycoside antibiotics market, which includes kanamycin, was valued at approximately $340 million in 2021.
• The market is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2022 through 2027, reaching approximately $440 million by 2027 (source: MarketsandMarkets).
• Kanamycin's specific market share within aminoglycosides is declining, attributed to the rise of newer antibiotics like amikacin and newer delivery modalities that diminish reliance on injectable aminoglycosides.

Key Market Drivers

• Increasing prevalence of MDR-TB: WHO reports approximately 450,000 cases of MDR-TB in 2021, constituting 6.2% of new TB cases worldwide (source: WHO). Kanamycin remains a component of second-line treatment regimens in many countries.
• Limited newer alternatives: Few effective, injectable options exist outside of aminoglycosides, maintaining a niche for kanamycin in certain contexts.
• Cost-effectiveness: Generic kanamycin is inexpensive compared to newer agents, influencing usage in low- and middle-income countries.

Market Challenges

• Toxicity concerns: Ototoxicity and nephrotoxicity limit long-term use, creating safety issues that favor newer agents with better side effect profiles.
• Resistance development: Rising resistance to aminoglycosides, including kanamycin, has led health authorities to limit its use, especially outside of MDR-TB treatment.
• Regulatory restrictions: Some countries restrict use due to safety risks, further constraining market growth.

Regulatory Trends

• The FDA has not approved new formulations of kanamycin since the 1970s.
• The WHO still recommends kanamycin in specific MDR-TB regimens but emphasizes surveillance for resistance and toxicity management.
• Several nations have phased out or limited prescription rights in favor of newer aminoglycosides like amikacin or capreomycin.

Financial Trajectory

• Revenue generation prospects are primarily confined to markets with high MDR-TB burdens, such as India, China, and parts of Africa.
• Established generic manufacturers dominate sales, with minimal investments in R&D for new formulations or delivery mechanisms.
• Patent expiry occurred decades ago, leading to price erosion and commoditization.
• Market growth is projected to be modest due to declining clinical use and regulatory restrictions.

Key Players

Company	Product	Market Share	Notes
Cipla	Generic kanamycin	Largest	Focused on low-cost markets, especially India
Mylan (now part of Viatris)	Generic formulations	Significant	Focus on MDR-TB regions
Local generic producers	Various	Variable	Predominant in emerging markets

Future Outlook

• The core market will remain limited to specific MDR-TB treatment contexts.
• No significant pipeline developments or new formulations are underway for kanamycin.
• Alternative aminoglycosides with better toxicity profiles may further erode kanamycin's share.
• Market value is unlikely to grow substantially without significant regulatory or clinical shifts.

Key Takeaways

• Kanamycin market is stable but declining, driven primarily by MDR-TB treatment needs in developing regions.
• Financial prospects are constrained by toxicity, resistance, and regulatory constraints.
• The market remains commoditized with little R&D activity, emphasizing generics sales in low-cost markets.
• Overall revenue trajectory suggests a slow or negative CAGR post-2027 unless new clinical indications or formulations emerge.

FAQs

1. What is the primary use of kanamycin today?
   It is mainly used in MDR-TB treatment regimens in low- and middle-income countries.

2. Why is the market for kanamycin shrinking?
   Due to toxicity concerns, rising resistance, regulatory restrictions, and the availability of newer agents with safer profiles.

3. Are there efforts to develop new formulations of kanamycin?
   No significant development is ongoing; focus remains on existing generic formulations.

4. What is the prognosis for kanamycin in MDR-TB treatment?
   It will likely remain part of some regimens but will decline as newer drugs replace it.

5. Which regions drive kanamycin sales?
   India, China, and certain African countries with high MDR-TB prevalence remain primary markets.

Sources

[1] MarketsandMarkets, "Aminoglycoside Antibiotics Market," 2022.
[2] World Health Organization, "Global Tuberculosis Report," 2022.
[3] FDA Drug Database, 2023.
[4] WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2022.